Gary Binder is a seasoned professional in health economics and outcomes research (HEOR) with extensive experience across various roles in the pharmaceutical industry. Currently serving as Sr. Director of HEOR at Cytokinetics since 2021, Binder leads US and global HEOR initiatives, emphasizing evidence plans and value propositions. Previously, at Helsinn Therapeutics from 2016 to 2021, Binder directed HEOR and market access strategies in oncology and hematology, identifying new unmet needs. Binder's earlier roles include Director of US Market Access at Celgene, where innovative value propositions were developed, and Director of Managed Care Strategy at Ferring Pharmaceuticals. With foundational leadership experience at Bristol-Myers Squibb, Horizon Blue Cross, and Schering-Plough, Binder's career is bolstered by an MBA in Strategy and Finance and a BS in Accounting and Decision Sciences from The Wharton School.
This person is not in any teams
This person is not in any offices